Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

MedPage Today·Jun 8

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Tolerability concerns have been raised for a GLP-1/glucagon agonist being studied for obesity and metabolic dysfunction-associated steatotic liver disease. However, the extent of these concerns is unclear, with some reports suggesting high dropout rates and others claiming tolerability is consistent with similar medications. Research on GLP-1 receptor agonists continues, with some studies showing promising results for weight loss and safety in treating obesity.

Full coverage

GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

The Lancet·Jan 15

ADA26: Survodutide's liver promise overshadowed by high dropout rates

FirstWord PHARMA·Jun 7

ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update

Fierce Biotech·Jun 8

EX-99.1

SEC.gov·May 11

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

MedPage Today·Jun 8

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Nature·Jun 7

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucos

PR Newswire·Apr 15

Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum

Frontiers·Apr 21

View original report at MedPage Today ↗

Fetching the latest headlines…